Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

1. Lau, G.
2. Abou-Alfa, G.K.
3. Cheng, A.-L.
4. Sukeepaisarnjaroen, W.
5. Van Dao, T.
6. Kang, Y.K.
7. Thungappa, S.C.
8. Kudo, M.
9. Sangro, B.
10. Kelley, R.K.
11. Furuse, J.
12. Park, J.-W.
13. Sunpaweravong, P.
14. Fasolo, A.
15. Yau, T.
16. Kawaoka, T.
17. Azevedo, S.
18. Reig, M.
19. Assenat, E.
20. Yarchoan, M.
21. He, A.R.
22. Makowsky, M.
23. Gupta, C.
24. Negro, A.
25. Chan, S.L.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.JHEP.2024.07.017 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus